Skip to main content
Clinical Trials/JPRN-jRCTb040230042
JPRN-jRCTb040230042
Recruiting
Phase 1

A clinical trial to evaluate the safety and tolerability of stem cells from human exfoliated deciduous teeth in children with cerebral palsy.

Sato Yoshiaki0 sites3 target enrollmentJune 22, 2023

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Sato Yoshiaki
Enrollment
3
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 22, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Sato Yoshiaki

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients aged 6 to 11 who were diagnosed with cerebral palsy at a medical institution
  • 2\) Patients diagnosed with neonatal hypoxic\-ischemic encephalopathy (HIE) at a medical institution
  • 3\) Patients with GMFCS level II or III
  • 4\) Patients with deciduous teeth that are slightly mobile or who have previously lost deciduous teeth
  • 5\) Patients with deciduous central or lateral incisors without cavity of C2 or higher
  • 6\) Patients who obtained written consent from the legal representative of the patient

Exclusion Criteria

  • 1\) Patients participating in other clinical trials (excluding observational studies)
  • 2\) Patients with confirmed or suspected severe congenital abnormalities or chromosomal abnormalities
  • 3\) Patients who have been judged by the attending physician to be unable to extract a tooth with local anesthesia
  • 4\) Patients undergoing or scheduled to undergo tendonectomy within one year
  • 5\) Patients who received botulinum toxin injection within 6 months
  • 6\) Patients with active or suspected serious infections
  • 7\) Patients who are positive for HBs antigen, HCV antibody, HIV antibody, HTLV\-1 antibody, or serologic test for syphilis
  • 8\) Patients diagnosed with diabetes
  • 9\) Patients with a history of severe hypersensitivity or anaphylactic reaction
  • 10\) Patients with other serious underlying diseases

Outcomes

Primary Outcomes

Not specified

Similar Trials